BioPartners GMBH isn't the only company vying for opportunities when patents on biologicals such as erythropoeitin (EPO) begin to expire in Europe, beginning as early as 2004. But the company has moved away from simply trying to re-produce existing products more cheaply—so-called "biogenerics". Instead, it's developing patented new formulations of therapeutic proteins that theoretically will offer concrete advantages over existing products, in terms of safety, dosing and price.
BioPartners' president and CEO Brian O'Callaghan is, like a growing number of industry players, skeptical as to whether simple copies...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?